Skip to main navigation Skip to search Skip to main content

Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts

  • Dedee F. Murrell
  • , Benjamin S. Daniel
  • , Pascal Joly
  • , Luca Borradori
  • , Masayuki Amagai
  • , Takashi Hashimoto
  • , Frédéric Caux
  • , Branka Marinovic
  • , Animesh A. Sinha
  • , Michael Hertl
  • , Philippe Bernard
  • , David Sirois
  • , Giuseppe Cianchini
  • , Janet A. Fairley
  • , Marcel F. Jonkman
  • , Amit G. Pandya
  • , David Rubenstein
  • , Detlef Zillikens
  • , Aimee S. Payne
  • , David Woodley
  • Giovanna Zambruno, Valeria Aoki, Carlo Pincelli, Luis Diaz, Russell P. Hall, Michael Meurer, Jose M. Mascaro, Enno Schmidt, Hiroshi Shimizu, John Zone, Robert Swerlick, Daniel Mimouni, Donna Culton, Jasna Lipozencic, Benjamin Bince, Sergei A. Grando, Jean Claude Bystryn, Victoria P. Werth
  • University of New South Wales
  • Keio University
  • SUNY Buffalo
  • IRCCS Istituto Dermopatico dell'Immacolata - Roma
  • University of North Carolina at Chapel Hill
  • CHU Hôpitaux de Rouen
  • University of Bern
  • Kurume University
  • Université Paris 13
  • University of Zagreb
  • University Hospital
  • Robert Debré University Hospital
  • New York University
  • University of Iowa
  • University of Groningen
  • University of Texas Southwestern Medical Center
  • University of Lübeck
  • University of Pennsylvania
  • University of Southern California
  • Universidade de São Paulo
  • University of Modena and Reggio Emilia
  • Duke University
  • Technische Universität Dresden
  • University of Barcelona
  • Hokkaido University
  • University of Utah
  • Emory University
  • Rabin Medical Center Israel
  • Department of Health Manila
  • University of California at Irvine
  • Department of Veterans Affairs

Research output: Contribution to journalReview articlepeer-review

342 Scopus citations

Abstract

Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies.

Original languageEnglish
Pages (from-to)479-485
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume66
Issue number3
DOIs
StatePublished - Mar 2012

Keywords

  • bullous pemphigoid
  • consensus
  • definitions
  • outcome measures
  • severity score

Fingerprint

Dive into the research topics of 'Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts'. Together they form a unique fingerprint.

Cite this